Amylin / Calcitonin
Typical Dosing Protocols (Research/Compounded Use Only) – Cagrilintide
Common protocol: 0.6–4.5 mg subcutaneously once weekly. Start with 0.6 mg once weekly and titrate upward every 2–4 weeks (e.g., 0.6 → 1.2 → 2.4 → 4.5 mg) to minimize gastrointestinal side effects.
Other reported ranges:
Standard maintenance: 2.4–4.5 mg once weekly
When stacked with semaglutide (CagriSema): 2.4 mg once weekly is commonly used
Titration period: Usually 4–16 weeks to reach target dose
Reconstitution example (for a typical 5 mg or 10 mg vial): Add 2 mL bacteriostatic water.
2.4 mg ≈ 0.48–0.96 mL (depending on final concentration)
4.5 mg ≈ 0.9–1.8 mL (adjust precisely)
Administration: Subcutaneous injection (abdomen, thigh, or upper arm) on the same day each week.
Dosing is highly individualized based on goals (weight loss, appetite control) and tolerance—consult a qualified healthcare provider experienced with incretin therapies for personalized guidance. This is for informational purposes only.
Key Potential Benefits of Cagrilintide
Strong Appetite Suppression and Satiety Enhancement
Acts as a long-acting amylin analog that activates amylin and calcitonin receptors in the brain (particularly area postrema), promoting powerful feelings of fullness and reducing hunger signals.
Helps users feel satisfied with smaller meals and decreases overall food cravings and caloric intake without relying solely on incretin pathways.
Provides complementary satiety signaling that works independently or synergistically with other weight-management mechanisms.
Significant Weight Loss and Fat Reduction
Delivers dose-dependent body weight reductions (up to ~10–11% at 4.5 mg weekly in monotherapy trials over 26 weeks).
Supports preferential loss of fat mass while helping preserve lean muscle tissue in research models.
Contributes to meaningful reductions in visceral and overall adipose tissue, especially when combined with lifestyle changes.
Slowed Gastric Emptying and Improved Metabolic Control
Delays gastric emptying to prolong the sensation of fullness after meals and stabilize postprandial glucose responses.
Supports better blood glucose regulation and may improve insulin sensitivity through amylin-mediated pathways.
Aids in overall metabolic health by reducing caloric load and enhancing nutrient handling.
Synergistic Effects in Combination Therapy
When paired with GLP-1 agonists like semaglutide (as CagriSema), produces additive or superior weight loss (often 15–22% in trials) through complementary mechanisms.
Enhances the efficacy of other appetite-regulating therapies while potentially offering a favorable tolerability profile in some aspects.
Provides amplified benefits for body composition, glycemic control, and cardiometabolic markers.
Support for Long-Term Weight Management
Long half-life enables convenient once-weekly dosing, improving adherence compared to daily regimens.
Helps sustain weight loss and metabolic improvements with continued use alongside diet and exercise.
May reduce the risk of weight regain by maintaining enhanced satiety signaling over time.
Broader Cardiometabolic and Vitality Benefits
Associated with improvements in lipids, blood pressure, and inflammatory markers in clinical studies.
Supports overall energy balance, physical well-being, and quality of life through effective weight and appetite management.
Contributes to healthier body composition and metabolic resilience as part of comprehensive wellness protocols.
Cagrilintide is a next-generation, long-acting synthetic amylin analog designed for weight management, with strong clinical data in monotherapy and combination settings.
